MindMed: Partnerships and Technology
Alright, so now that we have all the major trials and compounds pretty much covered, the third part of the MindMed process is the deploy phase. This is where their technology projects and other partnerships come into play. The chart below should give you a decent overview of the three biggest developments to come out of MindMed in this front.
Partner/Project Purpose
Project Albert JR (CEO) has been stressing the importance of Project Albert for some time now. He has repeatedly emphasized that MindMed is a drug development and technology company. Project Albert is based on designing and integrating digital therapeutic tools into the psychedelic-assisted psychotherapy process. They’re looking to integrate wearables, tracking, platforms, and other tools into the therapy process so that it can be more patient-personalized, effective, and informative. They’re also hoping that this part of the company improves the access people have to these medications through telemedicine.
MindMed + HealthMode MindMed added HealthMode to the company to expand Project Albert. Using AI, MindMed aims to help speed up the clinical research process and improve patient monitoring efforts. MindMed took on HealthMode’s entire team and portfolio and will begin to integrate what they have into the trails being developed as well as future patient monitoring platforms.
NYU Langone MindMed is now funding a program at NYU Langone Health to train and prepare the future psychedelic researchers and psychiatrists for the future when these drugs come to market. This isn’t so much a revenue-generating project as it will benefit the sector at large by having professionals prepared to deliver these therapies.
MindShift Compounds AG I know I touched on this briefly earlier, but the MindShift partnership is where MindMed will gain access to second-generation psychedelic compounds. We all know about the classical psychedelic compounds (LSD, Psilocybin, MDMA, DMT, etc.); second-gen compounds are being tailored specifically for different therapeutic purposes allowing companies to engineer more effective and, in some cases, safer compounds. Tons of companies are going down this path, so it’s good to have this partnership to add to the portfolio.
Hopefully that helps some of you out and get you familiar with MNMD. Below this is information on the compounds and trials that MNMD is pursuing. If you aren't interested in a bit of science feel free to cut it off here. If you are, keep reading.
